{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:55Z","timestamp":1787243395678,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed in solid tumours. Here, we report a case of brigatinib-induced TLS after treatment with sequential anaplastic lymphoma kinase (\n                    <jats:italic>ALK<\/jats:italic>\n                    ) inhibitors in a patient with advanced\n                    <jats:italic>ALK<\/jats:italic>\n                    -rearranged lung adenocarcinoma. The patient was treated sequentially with crizotinib, alectinib, and ensartinib. High-throughput molecular profiling after disease progression indicated that brigatinib may overcome\n                    <jats:italic>ALK<\/jats:italic>\n                    resistance mutations, so the patient was administered brigatinib as the fourth-line treatment. After 22\u00a0days of therapy, he developed oliguria, fever, and progressive dyspnoea. Clinical manifestations and laboratory findings met the diagnostic criteria for TLS. The significant decrease in the abundance of\n                    <jats:italic>ALK<\/jats:italic>\n                    mutations in plasma indicated a therapeutic response at the molecular level. Consequently, the diagnosis of brigatinib-induced TLS was established. To the best of our knowledge, this is the first case of TLS induced by sequential targeted therapy in non-small cell lung cancer. With the extensive application of sequential therapy with more potent next-generation targeted therapeutic drugs, special attention should be given to this rare but severe complication.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.809467","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:59:05Z","timestamp":1639969145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Yadong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s13730-015-0175-0","article-title":"Concurrent Acute Spontaneous Tumor Lysis Syndrome Complicated with Multiple Organ Failure in a Patient with Pre-existing Undiagnosed Lung Cancer","volume":"4","author":"Amiri","year":"2015","journal-title":"CEN Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","article-title":"Acute Tumor Lysis Syndrome in Solid Tumors-Aa Case Report and Review of the Literature","volume":"51","author":"Baeksgaard","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour Lysis Syndrome: New Therapeutic Strategies and Classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: An Expert TLS Panel Consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib Versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1200\/jco.20.00505","article-title":"Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/jco.2007.15.0177","article-title":"Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.Cd-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/ph13120474","article-title":"The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer","volume":"13","author":"Gristina","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"117822342110374","DOI":"10.1177\/11782234211037421","article-title":"Tumor Lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib","volume":"15","author":"Handy","year":"2021","journal-title":"Breast Cancer (Auckl)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The Tumor Lysis Syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.3748\/wjg.15.4464","article-title":"Sorafenib Induced Tumor Lysis Syndrome in an Advanced Hepatocellular Carcinoma Patient","volume":"15","author":"Huang","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the Management of Tumour Lysis Syndrome in Adults and Children with Haematological Malignancies on Behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2169\/internalmedicine.49.3153","article-title":"A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis Syndrome","volume":"49","author":"Joshita","year":"2010","journal-title":"Intern. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/jco.2016.71.5904","article-title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/jco.2007.14.7603","article-title":"Cetuximab-Related Tumor Lysis Syndrome in Metastatic colon Carcinoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s10637-009-9275-z","article-title":"Sunitinib Inducing Tumor Lysis Syndrome in a Patient Treated for Renal Carcinoma","volume":"28","author":"Michels","year":"2010","journal-title":"Invest. New Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.4081\/rt.2014.5389","article-title":"Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature","volume":"6","author":"Mirrakhimov","year":"2014","journal-title":"Rare Tumors"},{"key":"B21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrc.2015.03.002","article-title":"Tumor Lysis Syndrome in a Patient with Metastatic Non-small Cell Lung Cancer: Case Report and Literature Review","volume":"4","author":"Myint","year":"2015","journal-title":"Cancer Treat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/s0140-6736(07)60903-9","article-title":"Tumour Lysis Syndrome in a Patient with Renal-Cell Carcinoma Treated with Sunitinib Malate","volume":"369","author":"Nicholaou","year":"2007","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","article-title":"Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/jco.2008.19.4308","article-title":"Fatal Tumor Lysis Syndrome during Radiotherapy for Non-small-cell Lung Cancer","volume":"26","author":"Noh","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the First Move in EGFR-Driven or ALK-Driven NSCLC: First-Generation or Next-Generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.esmoop.2021.100164","article-title":"The Molecular Profiling of Solid Tumors by Liquid Biopsy: A Position Paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies","volume":"6","author":"Russo","year":"2021","journal-title":"ESMO Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/jco.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/hcn129","article-title":"Acute Spontaneous Tumor Lysis Syndrome in a Patient with Squamous Cell Carcinoma of the Lung","volume":"102","author":"Shenoy","year":"2009","journal-title":"QJM"},{"key":"B33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s12328-020-01306-1","article-title":"Lenvatinib-Induced Tumor Lysis Syndrome in a Patient with Advanced Hepatocellular Carcinoma: A Case Report","volume":"14","author":"Shimizu","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.athoracsur.2018.06.089","article-title":"Tumor Lysis Syndrome After Bilobectomy for Typical Carcinoid Tumor of the Lung","volume":"107","author":"Shin","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jtho.2020.09.018","article-title":"Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients with Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC","volume":"16","author":"Stinchcombe","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12328-020-01164-x","article-title":"Tumor Lysis Syndrome in a Patient with Metastatic Melanoma Treated with Nivolumab","volume":"13","author":"Sugimoto","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1111\/1346-8138.15894","article-title":"Tumor Lysis Syndrome Induced by BRAF\/MEK Double Blockade in a Patient with Metastatic Melanoma: A First Case Report","volume":"48","author":"Tachibana","year":"2021","journal-title":"J. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s2213-2600(18)30264-9","article-title":"Detection of EGFR Mutations in Plasma Circulating Tumour DNA as a Selection Criterion for First-Line Gefitinib Treatment in Patients with Advanced Lung Adenocarcinoma (BENEFIT): a Phase 2, Single-Arm, Multicentre Clinical Trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jtho.2021.01.1615","article-title":"Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing","volume":"16","author":"Yang","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s2213-2600(19)30252-8","article-title":"Efficacy, Safety, and Biomarker Analysis of Ensartinib in Crizotinib-Resistant, ALK-Positive Non-Small-Cell Lung Cancer: A Multicentre, Phase 2 Trial","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.Ccr-16-0569","article-title":"The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.809467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:59:07Z","timestamp":1639969147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.809467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":42,"alternative-id":["10.3389\/fphar.2021.809467"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.809467","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"article-number":"809467"}}